Structural aspects of the anti-cancer drug oxaliplatin: A combined theoretical and experimental study

被引:33
|
作者
Tyagi, Prateek [1 ]
Gahlot, Pragya [1 ]
Kakkar, Rita [1 ]
机构
[1] Univ Delhi, Dept Chem, Delhi 110007, India
关键词
Oxaliplatin; DFT; FT-IR; Anti-cancer; Conformation;
D O I
10.1016/j.poly.2008.08.025
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
The conformational behavior of the third generation antitumor drug, oxaliplatin, has been explored by GGA-PW91 density functional calculations and FT-IR spectra. The difference in the biological activities of cisplatin and oxaliplatin are attributed to the presence of the DACH ligand in the latter. The trans forms of the ligand are found to be more stable than the cis form, but, of the two equally stable enantiomers, the trans-1 (1R,2R) one is found to be more potent biologically. Since very minor differences are observed in the electronic structures of the two enantiomers, their difference in activity is attributed to the chiral recognition of the ligand by DNA. The calculated vibrational frequencies are in good agreement with our experimental FT-IR spectrum. Calculations have also been performed on the cis isomer and its monohydrate. Comparison between the theoretically predicted geometries and the experimental ones yielded good correspondence, validating our methodology. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3567 / 3574
页数:8
相关论文
共 50 条
  • [31] PEG based anti-cancer drug conjugated prodrug micelles for the delivery of anti-cancer agents
    Senevirathne, Suchithra A.
    Washington, Katherine E.
    Biewer, Michael C.
    Stefan, Mihaela C.
    JOURNAL OF MATERIALS CHEMISTRY B, 2016, 4 (03) : 360 - 370
  • [32] Study on thermochemotherapy using magnetic cationic liposomes and anti-cancer drug
    Yanase, M
    Shinkai, M
    Suzuki, M
    Honda, H
    Kobayashi, T
    KAGAKU KOGAKU RONBUNSHU, 1998, 24 (02) : 179 - 183
  • [33] Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates
    Wang, Nan
    Jiang, Xin
    Zhang, Shuo
    Zhu, Angqi
    Yuan, Yafei
    Xu, Hanwen
    Lei, Jianlin
    Yan, Chuangye
    CELL, 2021, 184 (02) : 370 - +
  • [34] ψ-Bufarenogin, a lead compound of anti-cancer drug
    Ding, Jin
    Wang, Hongyang
    CELL CYCLE, 2015, 14 (17) : 2719 - 2720
  • [35] PET in anti-cancer drug development and therapy
    Kumar, Rakesh
    Lal, Neena
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (03) : 259 - 263
  • [36] NEW APPROACH TO ANTI-CANCER DRUG DEVELOPMENT
    LANDES, RC
    BRITISH JOURNAL OF CANCER, 1975, 31 (02) : 254 - 254
  • [37] CYTEMBENA - ANTI-CANCER DRUG WITH AN UNIQUE STRUCTURE
    VONHOFF, DD
    ROZENCWEIG, M
    MUGGIA, FM
    BIOMEDICINE, 1977, 26 (06): : 388 - 392
  • [38] New anti-cancer photosensitizer drug developed
    Kashyap, Meenakshi
    NATIONAL MEDICAL JOURNAL OF INDIA, 2007, 20 (03): : 161 - 161
  • [39] EXPERIMENTAL-STUDY ON BONE-MARROW CFUS FOLLOWING ANTI-CANCER DRUG ADMINISTRATION TO PLETHORIC MICE
    MASSA, GG
    BOGLIOLO, GV
    SAVIANE, AG
    PANNACCIULLI, IM
    TUMORI, 1979, 65 (05) : 539 - 545
  • [40] Atropisomerism transforming anti-cancer drug discovery
    Patel, Simran
    Sandha, Khushi
    Waingankar, Anushka
    Jain, Prachi
    Abhyankar, Arundhati
    CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 101 (01) : 138 - 157